William Ackman
Bill Ackman runs hedge fund Pershing Square Capital, which he started in 2003 following the dissolution of Gotham Partners.
Ackman is a value investor with an activist bent. Activist investors agitate management for changes. He owns large positions in Target (NYSE: TGT) and Borders (NYSE: BGP). He has also been involved in activist situations at Wendy's (NYSE: WEN) and McDonald's (NYSE: MCD).
Ackman proved his acumen as a short seller in 2007/2008 as short positions he held in MBIA (NYSE: MBI) and Ambac (NYSE: ABK) proved to be big winners due to the credit crunch.
In July 2008, Ackman said he was short the common stock of Fannie Mae (NYSE: FNM) and Freddie Mac (NYSE: FRE). Ackman also laid out a plan to reorganize the GSEs, which would wipe out the common shareholders.
View Older Stories View More Recent Stories
-
Herbalife (HLF) Gains on Anti-Ackman Trade
-
Three Reasons Valeant (VRX) is Plunging Today
-
Ackman backs Valeant CEO as shares tumble to 2-1/2 year lows
-
Valeant (VRX) In Free Fall as Large Holders May Finally Be Crying Uncle
-
Ackman Stocks Trade Lower on Valeant (VRX) Free-Fall
-
Icahn Speculation Around Valeant (VRX) Grows Following Interview
-
Hedge fund Marcato gains 8.4 percent in October: source
-
Valeant's crisis fuels feud between Ackman and Australian fund manager Hempton
-
Ackman's fund lost 7.3 percent in October, off 19 percent for year
-
Bill Ackman's Pershing Square Down 19% YTD (VRX)
-
Goldman Sachs says Valeant has long road ahead, cuts rating
-
Citron's Left said "I have nothing with Bill Ackman. This is about Valeant (VRX)"
-
Citron publishes no new allegations against Valeant, shares rise
-
Citron Research: Don't Expect Anything Earth-Shattering on Valeant (VRX) Come Monday
-
Ackman lecture no match for Citron tweet as Valeant tumbles anew
-
Top 10 News for 10/26 - 10/30: Valeant's Saga Continues Marching Along; Walgreens Boots Moves to Acquire Rival
-
Valeant Pharma (VRX) Trades Near Lows Heading Into Weekend
-
Bill Ackman's conference call on Valeant Pharma (VRX) ends
-
Valeant Pharmaceuticals (VRX) Bull-Bear Debate Rages
-
Bill Ackman said their average cost on Valeant Pharma (VRX) is $186
-
Bill Ackman Said Fund 'Fully Invested'; 'Scraped Together Funds' to Buy Recent 2M Shares
-
Bill Ackman Compares Valeant Pharma (VRX) to American Express (AXP) in 1960s; Notes Buffett Bought on Panic
-
Bill Ackman said Valeant Pharma (VRX) worth $180-$240 Near-Term, $262-$350 Long-Term
-
Valeant (VRX) Trading at Less than 8X 2016 EPS Ex-Philidor - Ackman
-
Bill Ackman calls Valeant (VRX) Bausch & Lomb� 'best in the business'
-
Bill Ackman said the $100 million option on Philidor was for 'exclusivity' (VRX)
-
Ackman: Valeant's main problem is PR, not fraud
-
Amazon (AMZN) Should Distribute Drugs - Ackman
-
Pershing Square Valeant Pharma (VRX) Conf. Call Up and Running after Technical Difficulties
-
Valeant Pharma (VRX) on Watch as Ahead of Pershing Square Conference Call
-
I Hope Bill Ackman Has Done More Research on Valeant (VRX) Than Herbalife: Herbalife (HLF)
-
Herbalife Issues Statement Regarding Bill Ackman’s Presentation
-
William Green, Author Great Minds of Investing, Talks with Sarder TV About his Career as a Writer & Journalist
-
Valeant says Philidor pharmacy shutting down as it cuts ties
-
CVS, Express Scripts drop Valeant's Philidor; stock dives
-
Ackman's Pershing Square Down 15.9% YTD
-
ValueAct rallies Valeant investors as company fends off attack: source
-
Ackman to hold call to discuss investment in Valeant
-
Ackman's Pershing Square to Hold Conf. Call About Valeant Pharma (VRX) Investment
-
Pershing Square Holdings, Ltd. Announces Investor Call to Discuss its Investment in Valeant Pharmaceuticals International, Inc.
-
Short interest piled on Valeant ahead of scathing report
-
WPP Third Quarter Trading Update
-
Valeant slump poses big threat to small hedge funds
-
Valeant vows to refute 'phantom sales' allegations
-
Pershing Square's Ackman Down ~40% on Valeant Pharma (VRX) Bet
-
Ackman Affirms Buying Another 2M Valeant Pharma (VRX) Shares; Hasn't Sold Any - Bloomberg
-
UPDATE: Ackman Bought 2M More Shares of Valeant Pharma (VRX) - CNBC
-
Valeant meltdown costs investors billions; Ackman ups stake
-
Valeant shares plunge on short-seller scrutiny of pharmacy revenue
-
Hedge Funds on Edge as Valeant Pharma (VRX) Sinks

